|
gptkbp:instanceOf
|
gptkb:drug
gptkb:angiotensin_II_receptor_blocker
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
C09CA01
|
|
gptkbp:bioavailability
|
33%
|
|
gptkbp:brand
|
gptkb:Cozaar
|
|
gptkbp:CASNumber
|
124750-99-8
|
|
gptkbp:chemicalFormula
|
C22H22ClKN6O
|
|
gptkbp:combines
|
gptkb:hydrochlorothiazide
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to losartan
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
antihypertensive
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:form
|
100 mg
25 mg
50 mg
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
lithium
diuretics
potassium supplements
|
|
gptkbp:IUPACName
|
2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol potassium
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAsGeneric
|
true
|
|
gptkbp:mechanismOfAction
|
blocks angiotensin II receptor type 1 (AT1)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 6 years
|
|
gptkbp:patentExpired
|
2010
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:riskFactor
|
gptkb:angioedema
hypotension
renal impairment
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
cough
hyperkalemia
|
|
gptkbp:usedFor
|
heart failure
hypertension
diabetic nephropathy
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Seradane
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
losartan potassium
|